Clinical Trials Browser

Interventional × Mycosis Fungoides × Brentuximab Vedotin × Clear all

NCT01352520 2026-01-20

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Hematologic Diseases, Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT05357794 2026-01-12

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Phase 2 Recruiting

30 enrolled

Lymphoid

Mycosis Fungoides

NCT03587844 2025-11-03

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Phase 2 Recruiting

58 enrolled

Lymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis

NCT05414500 2025-08-08

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Phase 1 Recruiting

10 enrolled

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT01578499 2021-01-05

ALCANZA

Phase 3 Completed

131 enrolled 24 charts

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT02822586 2019-08-30

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

Phase 1 Completed

5 enrolled

Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT03373305 2019-04-30

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Phase 1 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT01396070 2017-04-05

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

Phase 2 Completed

36 enrolled 13 charts

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous